Sutro Biopharma (STRO)
(Delayed Data from NSDQ)
$3.72 USD
+0.02 (0.40%)
Updated Apr 23, 2024 03:59 PM ET
After-Market: $3.72 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Income Statements
Fiscal Year end for Sutro Biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 154 | 68 | 62 | 43 | 43 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 154 | 68 | 62 | 43 | 43 |
Selling & Adminstrative & Depr. & Amort Expenses | 243 | 197 | 160 | 114 | 98 |
Income After Depreciation & Amortization | -89 | -129 | -99 | -71 | -55 |
Non-Operating Income | 12 | 16 | -4 | 43 | 4 |
Interest Expense | 11 | 3 | 3 | 4 | 4 |
Pretax Income | -89 | -117 | -106 | -32 | -56 |
Income Taxes | 18 | 3 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -107 | -119 | -106 | -32 | -56 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -107 | -119 | -106 | -32 | -56 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -92 | -124 | -91 | -66 | -52 |
Depreciation & Amortization (Cash Flow) | -2 | 5 | 8 | 5 | 3 |
Income After Depreciation & Amortization | -89 | -129 | -99 | -71 | -55 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 60.16 | 50.74 | 46.12 | 32.57 | 22.96 |
Diluted EPS Before Non-Recurring Items | -1.91 | -2.35 | -2.06 | -2.00 | -2.43 |
Diluted Net EPS (GAAP) | -1.78 | -2.35 | -2.29 | -0.99 | -2.43 |
Fiscal Year end for Sutro Biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 113.72 | 16.92 | 10.41 | 12.67 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 113.72 | 16.92 | 10.41 | 12.67 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 70.57 | 60.94 | 56.59 | 54.91 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 43.15 | -44.02 | -46.18 | -42.24 |
Non-Operating Income | NA | 11.47 | -3.43 | 8.25 | -4.43 |
Interest Expense | NA | 7.75 | 0.00 | 0.44 | 2.99 |
Pretax Income | NA | 46.87 | -47.45 | -38.37 | -49.66 |
Income Taxes | NA | 15.81 | 1.84 | 0.15 | 0.40 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 31.07 | -49.28 | -38.52 | -50.05 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 31.07 | -49.28 | -38.52 | -50.05 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 59.74 | 60.60 | 60.34 | 58.72 |
Diluted EPS Before Non-Recurring Items | NA | 0.42 | -0.81 | -0.64 | -0.76 |
Diluted Net EPS (GAAP) | NA | 0.52 | -0.81 | -0.64 | -0.85 |